Aldurazyme and Kuvan Drive Revenue Growth in Q2 2012 – ‘Big Pharma’ Swoop Imminent

 - Written by Adefemi Adenuga, Analyst, Healthcare Industry Dynamics Team for GlobalData.

On August 2, 2012, BioMarin Pharmaceuticals, Inc. (BMRN) announced its second quarter financial results ending June 30, 2012. The Company posted a 12.1% increase in total revenue to $124.0m in Q2 2012 from $110.6m in Q2 2011. GlobalData ascribes this growth to a significant increase in sales from two of the company’s currently marketed products, Aldurazyme and Kuvan. Aldurazyme (laronidase), an enzyme replacement therapy for the treatment of mucopolysaccharidosis I (MPS I) manufactured by BioMarin and commercialized by Genzyme Corporation, grew worldwide by 26.0% year-to-year from $17.3m in Q2 2011 to $21.8m in Q2 2012. Kuvan (sapropterin hydrochloride), the first and only FDA approved drug for reducing blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA), grew by 20.5% from $28.8m in Q2 2011 to $34.7m in Q2 2012. BioMarin continued to experience incremental returns from its lead product, Naglazyme (galsaulfase), an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV (MPS IV), which grew by 4.3% from $60.3m in Q2 2011 to $62.9m in Q2 2012, accounting for 51.1% of the company’s revenue for the quarter.